EIF2AK3 and cancer: Our present work provides the explanation for the reason why drug-resistant cancer cells are prone to PERK inhibition and further suggests that PERK inhibitors provide a therapeutic opportunity for targeting cancer, in particular the drug-resistant cancer cells.